BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 34570200)

  • 1. CD158k and PD-1 expressions define heterogeneous subtypes of Sezary syndrome.
    Vergnolle I; Douat-Beyries C; Boulinguez S; Rieu JB; Vial JP; Baracou R; Boudot S; Cazeneuve A; Chaugne S; Durand M; Estival S; Lablanche N; Nicolau-Travers ML; Tournier E; Lamant L; Vergez F
    Blood Adv; 2022 Mar; 6(6):1813-1825. PubMed ID: 34570200
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CD158k is a reliable marker for diagnosis of Sézary syndrome and reveals an unprecedented heterogeneity of circulating malignant cells.
    Moins-Teisserenc H; Daubord M; Clave E; Douay C; Félix J; Marie-Cardine A; Ram-Wolff C; Maki G; Beldjord K; Homyrda L; Michel L; Bensussan A; Toubert A; Bagot M
    J Invest Dermatol; 2015 Jan; 135(1):247-257. PubMed ID: 25158034
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CD158k/KIR3DL2 is a useful marker for identifying neoplastic T-cells in Sézary syndrome by flow cytometry.
    Bahler DW; Hartung L; Hill S; Bowen GM; Vonderheid EC
    Cytometry B Clin Cytom; 2008 May; 74(3):156-62. PubMed ID: 18061949
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CD158k/KIR3DL2 is a new phenotypic marker of Sezary cells: relevance for the diagnosis and follow-up of Sezary syndrome.
    Poszepczynska-Guigné E; Schiavon V; D'Incan M; Echchakir H; Musette P; Ortonne N; Boumsell L; Moretta A; Bensussan A; Bagot M
    J Invest Dermatol; 2004 Mar; 122(3):820-3. PubMed ID: 15086570
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CD158K/KIR3DL2 transcript detection in lesional skin of patients with erythroderma is a tool for the diagnosis of Sézary syndrome.
    Ortonne N; Le Gouvello S; Mansour H; Poillet C; Martin N; Delfau-Larue MH; Leroy K; Farcet JP; Bagot M; Bensussan A
    J Invest Dermatol; 2008 Feb; 128(2):465-72. PubMed ID: 17703174
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The diagnosis of Sézary syndrome on peripheral blood by flow cytometry requires the use of multiple markers.
    Klemke CD; Brade J; Weckesser S; Sachse MM; Booken N; Neumaier M; Goerdt S; Nebe TC
    Br J Dermatol; 2008 Sep; 159(4):871-80. PubMed ID: 18652582
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Absolute CD3+ CD158k+ lymphocyte count is reliable and more sensitive than cytomorphology to evaluate blood tumour burden in Sézary syndrome.
    Bouaziz JD; Remtoula N; Bensussan A; Marie-Cardine A; Bagot M
    Br J Dermatol; 2010 Jan; 162(1):123-8. PubMed ID: 19681856
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Revisiting the initial diagnosis and blood staging of mycosis fungoides and Sézary syndrome with the KIR3DL2 marker.
    Roelens M; de Masson A; Ram-Wolff C; Maki G; Cayuela JM; Marie-Cardine A; Bensussan A; Toubert A; Bagot M; Moins-Teisserenc H
    Br J Dermatol; 2020 Jun; 182(6):1415-1422. PubMed ID: 31487384
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Use of the multiparametric panel CD3/CD4/CD8/CD7/CD26/CD158k in the detection and use of flow cytometry of Sezary cells].
    Callet J; Latger-Cannard V; Gérard D; Salignac S; Granel-Brocard F; Campidelli A; Bursztejn AC; Broséus J; Vial JP; Lesesve JF
    Ann Biol Clin (Paris); 2021 Jun; 79(3):233-240. PubMed ID: 34165432
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Histopathological and immunophenotypical criteria for the diagnosis of Sézary syndrome in differentiation from other erythrodermic skin diseases: a European Organisation for Research and Treatment of Cancer (EORTC) Cutaneous Lymphoma Task Force Study of 97 cases.
    Klemke CD; Booken N; Weiss C; Nicolay JP; Goerdt S; Felcht M; Géraud C; Kempf W; Assaf C; Ortonne N; Battistella M; Bagot M; Knobler R; Quaglino P; Arheiliger B; Santucci M; Jansen P; Vermeer MH; Willemze R
    Br J Dermatol; 2015 Jul; 173(1):93-105. PubMed ID: 25864856
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sezary syndrome: cutaneous immunoperoxidase double-labeling technique demonstrates CD4/CD8 ratio non-specificity.
    Balfour EM; Glusac EJ; Heald P; Talley LL; Smoller BR
    J Cutan Pathol; 2003 Aug; 30(7):437-42. PubMed ID: 12859741
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Significance of circulating T-cell clones in Sezary syndrome.
    Ortonne N; Huet D; Gaudez C; Marie-Cardine A; Schiavon V; Bagot M; Musette P; Bensussan A
    Blood; 2006 May; 107(10):4030-8. PubMed ID: 16418328
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Epidermotropic T cell lymphomas as models for tumor progression].
    Bagot M; Bensussan A
    Med Sci (Paris); 2006 Feb; 22(2):192-6. PubMed ID: 16457762
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Engagement of ILT2/CD85j in Sézary syndrome cells inhibits their CD3/TCR signaling.
    Nikolova M; Musette P; Bagot M; Boumsell L; Bensussan A
    Blood; 2002 Aug; 100(3):1019-25. PubMed ID: 12130517
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Blood flow cytometry in Sézary syndrome: new insights on prognostic relevance and immunophenotypic changes during follow-up.
    Novelli M; Fava P; Sarda C; Ponti R; Osella-Abate S; Savoia P; Bergallo M; Lisa F; Fierro MT; Quaglino P
    Am J Clin Pathol; 2015 Jan; 143(1):57-69. PubMed ID: 25511143
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PD-1 improves accurate detection of Sezary cells by flow cytometry in peripheral blood in mycosis fungoides/Sezary syndrome.
    Lewis NE; Gao Q; Petrova-Drus K; Pulitzer M; Sigler A; Baik J; Moskowitz AJ; Horwitz SM; Dogan A; Roshal M
    Cytometry B Clin Cytom; 2022 May; 102(3):189-198. PubMed ID: 35451196
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Naïve/memory T-cell phenotypes in leukemic cutaneous T-cell lymphoma: Putative cell of origin overlaps disease classification.
    Horna P; Moscinski LC; Sokol L; Shao H
    Cytometry B Clin Cytom; 2019 May; 96(3):234-241. PubMed ID: 30328260
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression and function of the natural cytotoxicity receptor NKp46 on circulating malignant CD4+ T lymphocytes of Sézary syndrome patients.
    Bensussan A; Remtoula N; Sivori S; Bagot M; Moretta A; Marie-Cardine A
    J Invest Dermatol; 2011 Apr; 131(4):969-76. PubMed ID: 21191411
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Polymorphic expression of CD158k/p140/KIR3DL2 in Sézary patients.
    Musette P; Michel L; Jean-Louis F; Bagot M; Bensussan A
    Blood; 2003 Feb; 101(3):1203. PubMed ID: 12529298
    [No Abstract]   [Full Text] [Related]  

  • 20. Membrane expression of NK receptors CD160 and CD158k contributes to delineate a unique CD4+ T-lymphocyte subset in normal and mycosis fungoides skin.
    Sako N; Schiavon V; Bounfour T; Dessirier V; Ortonne N; Olive D; Ram-Wolff C; Michel L; Sicard H; Marie-Cardine A; Bagot M; Bensussan A; Schmitt C
    Cytometry A; 2014 Oct; 85(10):869-82. PubMed ID: 25044837
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.